Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Evaxion presented promising results for its AI-designed vaccine, Genmab and Synact Pharma announced their Q2 reports, while Ascendis Pharma and Y-mAbs Therapeutics are set to release their Q2 reports this week.
Only 4 of the 20 listed, Danish biotech companies published news the past week. 8 of the 20 companies had a positive development in their share price for the week and 6 companies have had a positive share price performance year to date. Saniona continues to be the best performing stock this year with a price increase of more than 200%.
Company news the past week
Ascendis Pharma
Ascendis Pharma is set to release Q2 earnings on August 8 2023. The current target price from brokerages is $148.27 while the stock trades at $96.79.
No news the past week
Cessatech
No news the past week
No news the past week
No news the past week
Evaxion Biotech
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus(Link)
Evaxion announces financing commitments totaling up to USD 20 million with Global Growth Holding Limited (Link)
Expres2ion
No news the past week
Fluoguide
No news the past week
Genmab
Genmab Announced Financial Results for the First Half of 2023 (Link)
Gubra
No news the past week
Initiator Pharma
No news the past week
IO Biotech
No news the past week
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
Synact Pharma published its interim report for Q2 2023 (Link)
ViroGates
No news the past week
Zealand Pharma
No news the past week
Y-mAbs Therapeutics
Y-mAbs Therapeutics is set to announce its Q2 2023 results on August 10
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
On average, the Danish biotech stocks delivered a negative share price performance last week of -0.7%. Exres2ion Biotech Holding AB became the best performing stock with an 8% increase without announcing any company specific news. Notably, Evaxion Biotech delivered a negative share price return of 4% even though they announced promising results for EVX-B1 against Staphylococcus aureus as well as secured financial commitments of 20 MUSD. The best stocks year-to-date include Curasight, Fluoguide, and Saniona after soaring 81-201%. Overall the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 3.5%.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months